MetaCap

Lycia Therapeutics (LYCA) vs Replimune Group (REPL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Replimune Group is the larger company by market cap ($1.81 billion vs $1.72 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LYCA+10.23%REPL+66.40%
+109%+43%-22%
Oct 23, 20261 yearNov 20, 2026
LYCA+10.23%REPL+66.40%
+96%+40%-17%
Oct 19, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LYCA versus REPL key metrics
MetricLYCAREPL
Share price$33.07$19.07
Market cap$1.72B$1.81B
1-day change+4.09%-0.83%
YTD return—+96.19%
1-year return—+107.28%
5-year return—-34.24%
EPS (TTM)$-1.04$-2.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-313.94M
52-week high$36.49$23.54
52-week low$22.19$1.50
Distance from 52-week high-9.37%-18.99%
Analyst consensus—buy
Avg. price target upside—+33.72%
Average volume432.72K2.48M
Shares outstanding52.09M94.80M
Employees31465
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Lycia Therapeutics

LYCA stock →

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees

About Replimune Group

REPL stock →

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees

LYCA vs REPL FAQ

Which is bigger, Lycia Therapeutics or Replimune Group?

Replimune Group (REPL) is larger, with a market capitalization of $1.81B compared with $1.72B for Lycia Therapeutics (LYCA).

Are Lycia Therapeutics and Replimune Group in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons